版本:
中国

BRIEF-Aurinia announces that voclosporin achieves endpoints in its Phase IIB Aura-LV Study

Sept 29 Aurinia Pharmaceuticals Inc

* Comprehensive mortality review concludes deaths in aura-lv study appear to be unrelated to study drug and consistent with complications of ln

* Announces that Voclosporin achieves primary and all pre-specified secondary endpoints in its phase IIB Aura-LV study for Lupus Nephritis (ln) Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐